Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria
- National Institute for Health and Care Excellence - NICE
- National Institute for Health and Care Excellence (NICE);NHS England;NHS Improvement
- Publication date:
- 11 March 2021
This document will help inform Dr Hilary Cass’ independent review into gender identity services for children and young people. It was commissioned by NHS England and Improvement who commissioned the Cass review. It aims to assess the evidence for the clinical effectiveness, safety and cost-effectiveness of gonadotrophin releasing hormone (GnRH) analogues for children and adolescents aged 18 years or under with gender dysphoria. The document was prepared by NICE in October 2020.